Assessment of Oral Fluid HIV Test Performance in an HIV Pre-Exposure Prophylaxis Trial in Bangkok, Thailand

Authors

  • Pravan Suntharasamai Author
  • Michael Martin Author
  • Kachit Choopanya Author
  • Suphak Vanichseni Author
  • Udomsak Sangkum Author
  • Pairote Tararut Author
  • Wanna Leelawiwat Author
  • Rapeepan Anekvorapong Author
  • Philip A. Mock Author
  • Thitima Cherdtrakulkiat Author
  • Manoj Leethochawalit Author
  • Sithisat Chiamwongpaet Author
  • Roman J. Gvetadze Author
  • Janet M. McNicholl Author
  • Lynn A. Paxton Author
  • Somyot Kittimunkong Author
  • Marcel E. Curlin Author

Keywords:

Clinical Medicine & Pharmacology

Abstract

Background

Rapid easy-to-use HIV tests offer opportunities to increase HIV testing among populations at risk of infection. We used the OraQuick Rapid HIV-1/2 antibody test (OraQuick) in the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial among people who inject drugs.

Methods

The Bangkok Tenofovir Study was a randomized, double-blind, placebo-controlled trial. We tested participants’ oral fluid for HIV using OraQuick monthly and blood using a nucleic-acid amplification test (NAAT) every 3 months. We used Kaplan-Meier methods to estimate the duration from a positive HIV NAAT until the mid-point between the last non-reactive and first reactive oral fluid test and proportional hazards to examine factors associated with the time until the test was reactive.

Results

We screened 3678 people for HIV using OraQuick. Among 447 with reactive results, 436 (97.5%) were confirmed HIV-infected, 10 (2.2%) HIV-uninfected, and one (0.2%) had indeterminate results. Two participants with non-reactive OraQuick results were, in fact, HIV-infected at screening yielding 99.5% sensitivity, 99.7% specificity, a 97.8% positive predictive value, and a 99.9% negative predictive value. Participants receiving tenofovir took longer to develop a reactive OraQuick (191.8 days) than participants receiving placebo (16.8 days) (p = 0.02) and participants infected with HIV CRF01_AE developed a reactive OraQuick earlier than participants infected with other subtypes (p = 0.04).

Discussion

The oral fluid HIV test performed well at screening, suggesting it can be used when rapid results and non-invasive tools are preferred. However, participants receiving tenofovir took longer to develop a reactive oral fluid test result than those receiving placebo. Thus, among people using pre-exposure prophylaxis, a blood-based HIV test may be an appropriate choice.

Trial Registration

ClinicalTrials.gov NCT00119106.

Publication information

Originally published in PLOS ONE on 2015-12-30. Original DOI: 10.1371/journal.pone.0145859.

The original full text is available here under CC0 1.0. The displayed publication date is the original publication date.

Downloads

Original publication date

2015-12-30

Issue

Section

Research Articles